Quince Therapeutics, Inc. (QNCX) Financials

QNCX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 26.6 million 11.0 million
Dec. 31, 2025 93.5 million 129.2 million
Sept. 30, 2025 109.9 million 108.8 million
June 30, 2025 117.2 million 105.5 million

QNCX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -7.6 million 1.3 million
Dec. 31, 2025 -10.5 million 1.2 million
Sept. 30, 2025 -10.0 million 1.3 million
June 30, 2025 -11.5 million 1.3 million

QNCX Net Income

No data available :(

QNCX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 18.2 million - 293000
Dec. 31, 2025 17.8 million - 330000
Sept. 30, 2025 26.3 million - 359000
June 30, 2025 34.7 million 17.0 million 499000

QNCX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 5.0 million
Dec. 31, 2025 5.6 million
Sept. 30, 2025 5.4 million
June 30, 2025 4.7 million

QNCX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 4000 6.8 million 4.3 million -
Dec. 31, 2025 4000 12.6 million 3.6 million -
Sept. 30, 2025 74000 8.1 million 3.3 million -
June 30, 2025 126000 6.6 million 3.3 million -

QNCX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 36000
Dec. 31, 2025 - -
Sept. 30, 2025 - 36000
June 30, 2025 - 35000

QNCX

Price: $0.95

52 week price:
0.79
45.50

Earnings Per Share: -10.50 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 5.6 million

Links: